What Dertec Treats: Main Uses and Benefits

Dertec is a specialized combination cream commonly used in situations involving both inflammation and microbial infection, relevant when supportive symptom management is appropriate. This combination is used to treat skin inflammation and infections.

Combined Treatment for Infected Dermatoses

This formulation is primarily relevant for infected inflammatory dermatoses, such as eczema or dermatitis where a secondary infection has developed. It supports the management of conditions involving a mixture of fungal and bacterial pathogens, including complicated forms of Intertrigo and specific Tinea infections like Athlete's foot. This supports concurrent management of microbial growth and inflammation, which contributes to easing the overall symptom load.

Relief from Pronounced Inflammation and Itching

The medication is commonly used to address distressing symptomatic manifestations, including pruritus (itching), swelling, and redness (erythema), often applied during phases when symptoms become more noticeable. This symptomatic relief helps improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Mixed Skin Conditions Dertec is typically used in clinical scenarios marked by pronounced symptoms where short-term symptomatic assistance is needed for conditions complicated by microbial involvement.

Regulatory References

1. Hong Kong Department of Health

Eligibility Map: Who Can and Cannot Use Dertec

Official regulatory information for Dertec defines patient eligibility based on age, physiological status, and co-existing conditions.

Classification	Population or Condition	Regulatory Status
Contraindicated	Hypersensitivity to any component (Betamethasone, Clioquinol, Gentamicin, Tolnaftate)	Absolute Prohibition
	Viral skin lesions (e.g., Herpes Simplex, Varicella) or Tuberculous skin lesions	Absolute Prohibition
	Ophthalmic Use, Rosacea, or Perioral Dermatitis	Prohibition/Restriction
Pediatric Use	Children under 2 years of age	Not Recommended
	Children (due to higher absorption risk)	Caution/Special Precautions
Physiological Status	Pregnancy (Category C)	Caution, Avoid Extensive/Prolonged Use
	Lactation/Breastfeeding	Safety Not Absolutely Established

Use is also restricted on broken skin, cuts, or burns due to the increased risk of systemic absorption. Patients with co-existing conditions such as Impaired Renal Function, Diabetes, or Glaucoma should use the medicine with caution, as systemic absorption may exacerbate these issues.

Interactions with other medicines and products

The officially documented interaction profile for this combination is primarily structured around the potential for systemic absorption of its four active components. The risk of interaction is generally considered to be low with proper topical use, but specific cautions are stated in regulatory documentation regarding co-administration with certain drug classes.

---

Documented Drug-Drug Interactions

Interaction Type	Interacting Substances	Official Regulatory Outcome
Increased Systemic Exposure	CYP3A Inhibitors (e.g., Cobicistat-containing products), Other Topical Corticosteroids	Co-treatment may increase the risk of systemic effects from the Betamethasone component due to reduced clearance or additive systemic load.
Additive Toxicity	Potentially Neurotoxic / Nephrotoxic Drugs (e.g., Cisplatin, Vancomycin, Systemic Aminoglycosides), Potent Diuretics (e.g., Furosemide)	Concurrent use should be avoided as it reinforces the risk of neurotoxicity and/or nephrotoxicity associated with Gentamicin's potential systemic absorption.

---

Procedural and Population Interactions

The Clioquinol component may interfere with or alter the results of specific Thyroid Function Tests and can yield a false-positive result for the ferric chloride test for Phenylketonuria. The potential for component toxicity is officially noted as heightened in patients with renal or hepatic impairment, representing a population-specific interaction consideration.

Dertec's multimodal mechanism is defined by four complementary pharmacological actions. The corticosteroid component, Betamethasone Dipropionate, acts as a glucocorticoid receptor (GR) agonist, initiating genomic modulation that leads to the indirect inhibition of Phospholipase A2. This mechanism halts the synthesis of pro-inflammatory mediators like prostaglandins and leukotrienes, resulting in reduced tissue swelling, redness, and capillary permeability, and diminished transmission of local nociceptive signals.

Simultaneously, the combination provides dual anti-infective actions. Gentamicin is an inhibitor that disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to cellular failure. Tolnaftate acts as a specific inhibitor of Squalene Epoxidase, blocking the pathway necessary for fungal ergosterol synthesis. Furthermore, Clioquinol contributes via metal chelation, disrupting vital microbial enzymatic activity. This combination incorporates synergistic mechanisms where the anti-inflammatory action stabilizes the tissue environment, supporting the action of the anti-infective components on the microbial population.

How Dertec is Used: Official Administration Guidelines

Dertec, a four-component topical combination, is administered according to specific principles outlined in prescribing information. The medication is designated strictly for external, topical use as either a cream or an ointment. Its usage pattern is defined by a high-level schedule and duration limits, ensuring consistency with the intended short-course therapeutic approach.

---

Application and Frequency

Administration involves applying a thin film of the preparation to the skin surface, ensuring that the affected area is lightly covered. The standard regimen requires application two to three times daily, though this frequency may be adjusted based on the specific condition being managed. Unlike oral medications, timing in relation to food is not a consideration for this topical preparation.

---

Procedural Constraints and Duration

Official labeling includes explicit procedural restrictions to guide proper use. The treatment area must not be covered with occlusive dressings, plastic pants, or bandages unless specifically instructed by a healthcare provider. Furthermore, application must be avoided around sensitive areas, including the eyes, nose, and mouth.

Therapy duration is typically limited and determined by the resolution of the condition. For specific fungal issues, such as tinea pedis (Athlete's foot), a defined course of two to four weeks may be necessary. In pediatric patients (children), the duration of application is often limited to five days to minimize systemic exposure.

Research Evidence / Overview of Studies for Dertec

The research evidence for Dertec, a four-component fixed-dose combination, is structured around its intended use in situations involving both inflammation and microbial infection. Studies often involve the evaluation of this multimodal approach against other combination or single-agent therapies.

---

Evidence for Use in Infected Inflammatory Dermatoses

This section addresses the research exploring the use of the combination therapy for conditions like eczema or dermatitis that are complicated by secondary infection, which are considered conditions involving periods of heightened symptoms.

The available evidence primarily consists of short-term comparative clinical studies and Randomized Controlled Trials (RCTs). These studies research examined a diverse set of metrics, focusing on outcomes related to physical discomfort and clinical signs, alongside microbiological clearance. The main outcomes was studied for included the overall Therapeutic response, defined as the study's measurement of change (e.g., improvement or clearance of skin lesions), specific symptom changes (such as reduction in pruritus or itching, and erythema or redness), and Microbial Eradication, defined as the study's measurement of pathogen status (e.g., clearance of bacterial and fungal pathogens).

The findings describe patterns observed in the studies over short observation intervals, typically less than two weeks, reflecting the usual length of the studies. Because the combination was evaluated alongside other active treatments, the evidence provides context about how it was evaluated alongside alternative fixed combinations.

---

Evidence for Use in Inflamed Tinea Infections

Research has also explored the use of this combined therapy for common fungal skin infections, such as Athlete's foot or ringworm, particularly when they present as conditions associated with acute or disruptive episodes of inflammation and intense itching.

The evidence structure here involves comparative studies and RCTs where the combination was evaluated in research that included antifungal-only monotherapy and other combination products. Researchers monitored two main axes of change: the Clinical Cure Rates, defined as the study's measurement of disease status (e.g., resolution of visible signs) and Mycological Cure, defined as the study's measurement of fungal status (e.g., eradication of the fungus), as well as the Time to Symptom Relief.

---

What is Still Uncertain in the Research Record

The existing research describes the short-term changes that were observed, but the overall scientific review highlights several limitations and areas of uncertainty. The data base for the exact four-component formula is often less extensive than that available for dual- or triple-component combinations. Furthermore, the reliance on short-term trials means that follow-up durations were limited. Evidence concerning the long-term impact on the affected skin, information related to symptom patterns following the end of the study period, and performance in certain specific populations (like those with compromised immune systems) remains an area where further research is needed.

Common questions about Dertec (FAQ)

---

Q: What should I do if I miss a dose of Dertec?

Official administration guidelines often state that if a dose of Dertec is missed, applying it as soon as it is remembered is the usual approach. However, if it is nearly time for the next scheduled application, the usual recommendation is to skip the missed application and continue with the regular schedule. The labeling advises against applying a double amount to compensate for a missed application.

---

Q: Who should not use Dertec?

Regulatory information defines specific conditions and groups of people who should not use Dertec. Contraindications include known hypersensitivity or allergy to any of the four active components (Betamethasone, Clioquinol, Gentamicin, or Tolnaftate). Furthermore, regulatory documents state that Dertec should not be used in the presence of skin conditions like viral lesions (such as Herpes Simplex or Varicella), tuberculous lesions, rosacea, or perioral dermatitis.

---

Q: What is the main purpose of the corticosteroid component in Dertec?

The corticosteroid component, Betamethasone Dipropionate, is included to provide potent anti-inflammatory and antipruritic actions. Its primary function is to help relieve inflammatory symptoms associated with the skin condition, such as redness, itching, and swelling. This component is included to provide relief from inflammatory symptoms.

---

Q: Is a prescription needed to get Dertec?

According to the general classification found in official regulatory documents, Dertec is generally categorized as a prescription-only medication. This classification is based on its composition, which includes a potent corticosteroid (Betamethasone Dipropionate) and an aminoglycoside antibiotic (Gentamicin).

---

Q: How quickly can I expect symptom relief (e.g., itching reduction) after starting Dertec?

Clinical studies often measure metrics like the 'Time to Symptom Relief' to evaluate the product's effectiveness. While the anti-inflammatory component is generally designed to act relatively quickly, the full therapeutic effect depends on the specific condition being treated. For specific information on when relief might be expected, consult the prescribing healthcare provider.

---

Q: What should I do if I accidentally swallow Dertec?

Dertec is a topical product and is not intended for ingestion. Official safety information regarding accidental ingestion states that if a large amount is swallowed, a poison control center should be contacted. Seeking prompt medical attention may be indicated depending on the quantity ingested.

How to Store and Dispose of Dertec?

Dertec, a topical combination preparation, requires specific conditions to maintain its labeled stability. The product must be stored below 30 C (86 F) and must not be frozen. Storage requirements include protection from light, and the container must be kept tightly closed to maintain product integrity.

Child-Safety and Disposal

All medicines, including Dertec, must be kept out of the reach of children. Disposal of unused or expired Dertec should be carried out strictly according to local regulations. To protect the environment, the product should not be disposed of in household trash or wastewater and must be directed to an approved pharmaceutical waste disposal channel.